Transforming medicine

Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ 

Acacia Pharma Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support US Launches of BARHEMSYS® and BYFAVO™

Acacia Pharma Announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

Results of Placing

Interim Results for the Six Months ended 30 June 2020

Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®

Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

Acacia Pharma Announces Debt for Equity Swap with Cosmo Pharmaceuticals

Alessandro Della Chà Appointed as Director of Acacia Pharma Group plc

Acacia Pharma Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

Acacia Pharma Announces Changes to its Officers and Board of Directors

Results for the Year ended 31 December 2019

Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

Acacia Pharma Wins BEL Small Company of the Year 2019

Acacia Pharma Announces Planned CFO Succession

Acacia Pharma Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.